Abstracts tagged "Vasculitis"

Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 0754 • ACR Convergence 2024
Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Carmen Secada Gómez¹, Javier Loricera², Adrián Martín-Gutiérrez³, Fernando Lopez-Gutierrez⁴, María Nuñez-Sayar⁵, Ander Ucelay-Aristi⁵, Isabel Martinez-Rodriguez⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco-Alonso⁹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁵Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis and periaortitis represent the inflammation of the aortic wall and the surrounding periaortic tissues, respectively. Both can be idiopathic or secondary to infectious…
Abstract Number: 0854 • ACR Convergence 2024
The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Valentin Sebastian Schäfer¹, Tobias Schremmer², Florian Recker³, Wolfgang Hartung⁴, Christina Duftner⁵, Sara Monti⁶, Alojzija Hocevar⁷, Rositsa Karalilova⁸, Annamaria Iagnocco⁹, pierluigi macchioni¹⁰, Giuseppe Antonio Germano¹¹, ESPERANZA NAREDO¹², Eugenio De Miguel¹³, Luca Seitz¹⁴, Thomas Daikeler¹⁵, Dennis Boumans¹⁶, Chetan Mukhtyar¹⁷, Kate Smith¹⁸, Richard Wakefield¹⁸, Andreas Diamantopoulos¹⁹, Stavros Chrysidis²⁰, Berit Dalsgaard Nielsen²¹, Kresten Keller²², Uffe Moller Dohn²³, Lene Terslev²⁴, Marcin Milchert²⁵, Wolfgang Schmidt²⁶, George A. W. Bruyn²⁷, Aaron Juche²⁸ and Christian Dejaco²⁹, ¹Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, 53127 Bonn, Nordrhein-Westfalen, Germany, ²Helios Klinikum Bonn/Rhein-Sieg, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Germany, Bonn, Germany, ⁴Asklepios Clinic, Tegernheim, Germany, ⁵Medical University Innsbruck/Tirol Kliniken GmbH, Innsbruck, Austria, ⁶IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁷University Medical Center Ljubljana, LJUBLJANA, Slovenia, ⁸Medical University of Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁹University of Turin, Italy, Roma, Italy, ¹⁰SERVIZIO REUMATOLOGIA IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ¹¹Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, ¹²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Inselspital, Liebefeld, Switzerland, ¹⁵university hospital, Basel, Switzerland, ¹⁶Ziekenhuisgroep Twente (Hospital Group Twente), Borne, Netherlands, ¹⁷Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁸NIHR Leeds Biomedical Research Centre, Leeds, UK., Leeds, United Kingdom, ¹⁹Akershus University Hospital, Lørenskog, Norway, ²⁰Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ²¹Department of Rheumatology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, Vejle, Denmark, ²²Aarhus University Hospital, Aarhus, Denmark, ²³Rigshospitalet-Glostrup, Glostrup, Denmark, ²⁴Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ²⁵Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology, Pomeranian Medical University, Szczecin, Poland., Szczecin, Poland, ²⁶Immanuel Krankenhaus Berlin, Berlin, Germany, ²⁷Reumakliniek Lelystad, Loenga, Netherlands, ²⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, Berlin, Germany, ²⁹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). Due to the urgent need for glucocorticoid treatment in acute GCA…
Abstract Number: 1616 • ACR Convergence 2024
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Gaston Ariel Ghio¹, Marta Domínguez-Álvaro², Ricardo Blanco-Alonso³, Santos Castañeda⁴, Iñigo Hernández-Rodríguez⁵, Elisa Fernández-Fernández:⁶, Maite Silva-Diaz⁷, Joaquin María Belzunegui:⁸, Clara Moriano⁹, Julio Sánchez-Martín¹⁰, Javier Narvaez-García¹¹, Eva Galindez¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuán¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota L Iñiguez:¹⁷, Alicia García Dorta¹⁸, Clara Molina Almela¹⁹ and María Alcalde Villar:²⁰, and ARTESER Project Collaborative Group, ¹Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁷Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸H de Donostia, Donostia-San Sebasti, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Hospital Universitario de Cabueñes, Bilbao, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁸Rheumatologist, La Laguna, Spain, ¹⁹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁰Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 2496 • ACR Convergence 2024
Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
Abstract Number: 2520 • ACR Convergence 2024
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Peter Merkel¹, Yi Peng², Patrick Zueger², Clara Ziadeh³, Ana B. Romero⁴, Richard Thielen³ and Denise Kruzikas³, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc, North Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
Abstract Number: 0720 • ACR Convergence 2024
Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care
javier Merayo Chalico¹, Ana Sarahí Mulia-Soto², María Espinosa-León³, Victor Pimentel-Quiroz⁴, Ana Barrera-Vargas³ and Andrea Hinojosa-Azaola³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁴Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru
Background/Purpose: Systemic vasculitides comprise a group of inflammatory diseases involving multiple organ systems, significantly affecting various aspects of a patient's life, including their sexuality. Sexual…
Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Ali Raza Khan¹, Nouman Shafique², Abdul Qadeer¹ and zaigham Shaukat¹, ¹Nishtar Medical University, Multan, Punjab, Pakistan, ²AdventHealth Orlando, Orlando, FL
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…
Abstract Number: 0855 • ACR Convergence 2024
Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study
Alexandra Kachaner¹, Arthur Mageau¹, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 1884 • ACR Convergence 2024
VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach
Stephen Williams, Stephanie Garner and Aurore Fifi-Mah, University of Calgary, Calgary, AB, Canada
Background/Purpose: The vasculitides are rare but serious conditions that are characterized by the destructive inflammation of the blood vessels. Patients living with vasculitis are often considered…
Abstract Number: 2497 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³, Ansaam Daoud⁴, Loai Dweik⁵, Hashim Syed⁶ and Omer Pamuk⁷, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁶Case Western/ UH, Cleveland, ⁷University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem. There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Salma Al Fazazi³, Vanesa Calvo-Rio⁴, Mónica Renuncio-García⁵, Adrián Martín-Gutiérrez⁶, Amparo Sánchez-López⁷, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁷, Maria Rodríguez-Vidriales¹ and Ricardo Blanco-Alonso⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ³Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].